Mathias Jachs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mathias Jachs has a total of 476 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Reiberger
Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
57 shared publications - Mattias Mandorfer
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
47 shared publications - Lukas Hartl
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
34 shared publications - Lorenz Balcar
Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria
32 shared publications - Benedikt Simbrunner
Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria
29 shared publications - Georg Semmler
Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria
29 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11)
Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC
Background and Aims: The applicability of non‐invasive tests (NITs) for clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC) is controversial. We performed a head‐to‐head comparison of various NITs for CSPH and evaluated rule‐in/‐out criteria. Methods: We conducted a retrospective study including 283 patients with HCC undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna Hepatic Haemodynamic Lab with available, same‐day data on NITs (i.e., liver stiffness measurement [LSM], platelet count [PLT], von Willebrand factor antigen [VWF:Ag], and the ratio of VWF:Ag and PLT [VITRO]). For the subsequent analysis, we focused on patients with compensated advanced chronic liver disease (cACLD). Results: Among 164 patients with cACLD, most were BCLC 0/A (50.6%) and CSPH prevalence was 46.3%, the median LSM was 20.0 kPa (IQR: 13.3–37.9), and mean VWF:Ag/VITRO was 266 ± 119%/2.30 ± 1.81. The VITRO score yielded the highest discriminative ability to detect CSPH (AUROC: 0.834), followed by ANTICIPATE ± NASH (AUROC: 0.822), PLT (AUROC: 0.803), LSM (AUROC: 0.779), and VWF:Ag (AUROC: 0.707). The application of the Baveno VII criterium (LSM ≤ 15 kPa & PLT ≥ 150G/L) and the VITRO score (≤ 1.0) individually showed an excellent performance for ruling‐out CSPH (sensitivities: ≥ 95%, NPV: 100%/87.9%). For ruling‐in CSPH by individual criteria, the VITRO score provided the highest PPV (≥ 2.5, specificity/PPV: 89.8%/83.0%), followed by the Baveno VII criteria (specificity/PPV: 81.8%/74.6%). When sequentially applying Baveno VII criteria and VITRO, the grey zone could be significantly reduced to 16% (sensitivity/NPV: 94.7%/92.2%; specificity/PPV: 73.9%/84.4%). Conclusion: The discriminative ability in patients with cACLD and HCC was comparable to patients without HCC. However, PPVs of established criteria were < 90%, which may be explained by the comparatively low prevalence of CSPH in this context.
- 26 October 2026
- Published by Wiley in Liver International
- Vol. 46 (11)
Open AccessBlood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC
Background and Aims: The applicability of non‐invasive tests (NITs) for clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC) is controversial. We performed a head‐to‐head comparison of various NITs for CSPH and evaluated rule‐in/‐out criteria. Methods: We conducted a retrospective study including 283 patients with HCC undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna Hepatic Haemodynamic Lab with available, same‐day data on NITs (i.e., liver stiffness measurement [LSM], platelet count [PLT], von Willebrand factor antigen [VWF:Ag], and the ratio of VWF:Ag and PLT [VITRO]). For the subsequent analysis, we focused on patients with compensated advanced chronic liver disease (cACLD). Results: Among 164 patients with cACLD, most were BCLC 0/A (50.6%) and CSPH prevalence was 46.3%, the median LSM was 20.0 kPa (IQR: 13.3–37.9), and mean VWF:Ag/VITRO was 266 ± 119%/2.30 ± 1.81. The VITRO score yielded the highest discriminative ability to detect CSPH (AUROC: 0.834), followed by ANTICIPATE ± NASH (AUROC: 0.822), PLT (AUROC: 0.803), LSM (AUROC: 0.779), and VWF:Ag (AUROC: 0.707). The application of the Baveno VII criterium (LSM ≤ 15 kPa & PLT ≥ 150G/L) and the VITRO score (≤ 1.0) individually showed an excellent performance for ruling‐out CSPH (sensitivities: ≥ 95%, NPV: 100%/87.9%). For ruling‐in CSPH by individual criteria, the VITRO score provided the highest PPV (≥ 2.5, specificity/PPV: 89.8%/83.0%), followed by the Baveno VII criteria (specificity/PPV: 81.8%/74.6%). When sequentially applying Baveno VII criteria and VITRO, the grey zone could be significantly reduced to 16% (sensitivity/NPV: 94.7%/92.2%; specificity/PPV: 73.9%/84.4%). Conclusion: The discriminative ability in patients with cACLD and HCC was comparable to patients without HCC. However, PPVs of established criteria were < 90%, which may be explained by the comparatively low prevalence of CSPH in this context.
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (11)
Lower circulating angiotensinogen levels across ACLD stages are associated with hepatic dysfunction and mortality
Introduction: The liver produces angiotensinogen (AGT), the key upstream precursor of the renin-angiotensin system (RAS). We measured AGT levels in patients across distinct advanced chronic liver disease (ACLD) stages and investigated the impact of AGT levels on clinical outcomes. Methods: We included clinically stable ACLD outpatients undergoing hepatic venous pressure gradient (HVPG) measurement between May 2018 and October 2023, as well as healthy controls (HCs) recruited in the prospective Vienna Cirrhosis Study (VICIS; NCT03267615). AGT was assessed by converting it to angiotensin I (Ang I) through incubation with excess recombinant human renin. RAS parameters were measured by liquid chromatography-tandem mass spectrometry. Patients were stratified as compensated (cACLD), single decompensated (sdACLD), or further decompensated ACLD (fdACLD). Results: Overall, 60 individuals (cACLD: n=16; sdACLD: n=22; fdACLD: n=12; HC: n=10) were included. AGT levels decreased significantly compared with HC and with increasing ACLD severity (HC: 943.2 vs. cACLD: 550.4 vs. sdACLD: 476.9 vs. fdACLD: 439.8 nmol/L; p p =0.002) and Ang 1-7 (cACLD: 3.0 vs. sdACLD: 3.2 vs. fdACLD: 8.5 pmol/L; p =0.022) increased significantly with ACLD severity. AGT did not correlate with Ang II (ρ=−0.23; p =0.101), but with Ang 1-7 (ρ=0.32; p =0.022) and MELD-Na (ρ=−0.29; p =0.042). Exploratory survival analyses, limited by the small sample size, showed that lower AGT was associated with all-cause mortality (adjusted for age and MELD-Na: asHR: 1.59; 95% CI: 1.09–2.27; p =0.012/adjusted for age and albumin: asHR: 1.52; 95% CI: 1.05–2.21; p =0.026). Conclusions: AGT levels decreased in ACLD, correlated with hepatic dysfunction, and were linked to all-cause mortality in exploratory survival analyses. Still, classical and alternative RAS parameters increased in parallel to ACLD severity.
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (11)
Open AccessLower circulating angiotensinogen levels across ACLD stages are associated with hepatic dysfunction and mortality
Introduction: The liver produces angiotensinogen (AGT), the key upstream precursor of the renin-angiotensin system (RAS). We measured AGT levels in patients across distinct advanced chronic liver disease (ACLD) stages and investigated the impact of AGT levels on clinical outcomes. Methods: We included clinically stable ACLD outpatients undergoing hepatic venous pressure gradient (HVPG) measurement between May 2018 and October 2023, as well as healthy controls (HCs) recruited in the prospective Vienna Cirrhosis Study (VICIS; NCT03267615). AGT was assessed by converting it to angiotensin I (Ang I) through incubation with excess recombinant human renin. RAS parameters were measured by liquid chromatography-tandem mass spectrometry. Patients were stratified as compensated (cACLD), single decompensated (sdACLD), or further decompensated ACLD (fdACLD). Results: Overall, 60 individuals (cACLD: n=16; sdACLD: n=22; fdACLD: n=12; HC: n=10) were included. AGT levels decreased significantly compared with HC and with increasing ACLD severity (HC: 943.2 vs. cACLD: 550.4 vs. sdACLD: 476.9 vs. fdACLD: 439.8 nmol/L; p p =0.002) and Ang 1-7 (cACLD: 3.0 vs. sdACLD: 3.2 vs. fdACLD: 8.5 pmol/L; p =0.022) increased significantly with ACLD severity. AGT did not correlate with Ang II (ρ=−0.23; p =0.101), but with Ang 1-7 (ρ=0.32; p =0.022) and MELD-Na (ρ=−0.29; p =0.042). Exploratory survival analyses, limited by the small sample size, showed that lower AGT was associated with all-cause mortality (adjusted for age and MELD-Na: asHR: 1.59; 95% CI: 1.09–2.27; p =0.012/adjusted for age and albumin: asHR: 1.52; 95% CI: 1.05–2.21; p =0.026). Conclusions: AGT levels decreased in ACLD, correlated with hepatic dysfunction, and were linked to all-cause mortality in exploratory survival analyses. Still, classical and alternative RAS parameters increased in parallel to ACLD severity.
- Open Access
- 9 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70778
Changes in SSM Assessed via 100 Hz ‐ VCTE Are Associated With Acute HVPG ‐Response to i.v. Propranolol: A European Multicentre Study
Background: The acute hepatic venous pressure gradient (HVPG)‐response to i.v. propranolol predicts outcomes in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH). While non‐invasive tests (NIT) to monitor non‐selective beta‐blocker (NSBB)‐induced HVPG changes are lacking, spleen stiffness measurement (SSM) has shown promising results as a surrogate for HVPG. This study aimed to assess the correlation between changes in SSM at 100 Hz and HVPG upon acute i.v. propranolol. Methods: ACLD patients with CSPH undergoing paired HVPG and SSM‐100 Hz assessments pre‐ and post‐i.v. propranolol (0.15 mg/kg) at three expert centres between 2019 and 2024 were included. HVPG‐response was defined as a ≥ 10% decrease in HVPG. Results: Ninety‐four patients (63.8% males, median age 57.5 [Q1–Q3: 50.0–65.0] years, BMI 26.6 [22.8–31.1] kg/m 2 ) were included. Most had alcohol‐related liver disease (ALD)/metabolic‐associated liver disease (59.6%) or metabolic‐associated steatotic liver disease (11.7%). The median HVPG decreased from 17 (Q1–Q3: 15–20) mmHg to 16 (Q1–Q3: 12–19) mmHg post‐NSBB ( p < 0.001), with 45.7% achieving an acute HVPG‐response. SSM decreased by −8.7 ([Q1–Q3: −19.2; −0.2] kPa, p < 0.001). HVPG‐responders had a significant SSM decrease (−12.4 [Q1–Q3: −26.3; −5.6] kPa, p < 0.001), while non‐responders showed no change. A moderate correlation between relative changes in SSM and HVPG was observed (Spearman's ρ: 0.387; p < 0.001). Relative change in SSM achieved an area under the receiver operating characteristic curve (AUROC) of 0.717 (95% CI: 0.614–0.820, p < 0.001) for diagnosing HVPG‐response. Conclusion: SSM‐100 Hz dynamics are associated with HVPG changes upon i.v. propranolol administration. Although the discriminative ability of changes in SSM was insufficient for clinical use, they may serve as a surrogate of efficacy in clinical trials investigating medical therapies for portal hypertension.
- 9 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70778
Open AccessChanges in SSM Assessed via 100 Hz ‐ VCTE Are Associated With Acute HVPG ‐Response to i.v. Propranolol: A European Multicentre Study
Background: The acute hepatic venous pressure gradient (HVPG)‐response to i.v. propranolol predicts outcomes in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH). While non‐invasive tests (NIT) to monitor non‐selective beta‐blocker (NSBB)‐induced HVPG changes are lacking, spleen stiffness measurement (SSM) has shown promising results as a surrogate for HVPG. This study aimed to assess the correlation between changes in SSM at 100 Hz and HVPG upon acute i.v. propranolol. Methods: ACLD patients with CSPH undergoing paired HVPG and SSM‐100 Hz assessments pre‐ and post‐i.v. propranolol (0.15 mg/kg) at three expert centres between 2019 and 2024 were included. HVPG‐response was defined as a ≥ 10% decrease in HVPG. Results: Ninety‐four patients (63.8% males, median age 57.5 [Q1–Q3: 50.0–65.0] years, BMI 26.6 [22.8–31.1] kg/m 2 ) were included. Most had alcohol‐related liver disease (ALD)/metabolic‐associated liver disease (59.6%) or metabolic‐associated steatotic liver disease (11.7%). The median HVPG decreased from 17 (Q1–Q3: 15–20) mmHg to 16 (Q1–Q3: 12–19) mmHg post‐NSBB ( p < 0.001), with 45.7% achieving an acute HVPG‐response. SSM decreased by −8.7 ([Q1–Q3: −19.2; −0.2] kPa, p < 0.001). HVPG‐responders had a significant SSM decrease (−12.4 [Q1–Q3: −26.3; −5.6] kPa, p < 0.001), while non‐responders showed no change. A moderate correlation between relative changes in SSM and HVPG was observed (Spearman's ρ: 0.387; p < 0.001). Relative change in SSM achieved an area under the receiver operating characteristic curve (AUROC) of 0.717 (95% CI: 0.614–0.820, p < 0.001) for diagnosing HVPG‐response. Conclusion: SSM‐100 Hz dynamics are associated with HVPG changes upon i.v. propranolol administration. Although the discriminative ability of changes in SSM was insufficient for clinical use, they may serve as a surrogate of efficacy in clinical trials investigating medical therapies for portal hypertension.
- Open Access
- 11 June 2026
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (21-22) , 697-700
Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D
Summary: Treatment options for chronic hepatitis D (CHD) are limited in patients who do not respond to recommended treatment with bulevirtide ± pegylated interferon. The use of REP 2139-Mg is a novel treatment option that has recently demonstrated efficacy and safety in phase 2 trials and a compassionate access program that included three patients treated at the Vienna General Hospital with compensated advanced chronic liver disease and clinically significant portal hypertension (CSPH). Long-term outcome of CSPH patients treated with REP 2139-Mg is unknown; thus, surrogate endpoints are of interest in this population. In the 3 patients receiving REP 2139-Mg for 12 months at our center, we monitored the hepatic venous pressure gradient (HVPG) as the strongest prognostic surrogate biomarker in compensated cirrhosis at baseline, and after 3 and 12 months of treatment. The HVPG dynamics alongside additional liver function tests observed are summarized in this report and two out of three patients achieved undetectable hepatitis-D-virus(HDV)-RNA and low hepatitis B surface Antigen (HBsAg) following pronounced alanine aminotransferase (ALT) flares during REP 2139-Mg treatment. The first patient showed virologic non-response and no HVPG dynamics during treatment. The second patient developed jaundice upon treatment initiation, resulting in a transient increase in HVPG despite virologic response. The third patient achieved virologic response that was paralleled by sustained reductions in HVPG.
- 11 June 2026
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (21-22) , 697-700
Open AccessEvolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D
Summary: Treatment options for chronic hepatitis D (CHD) are limited in patients who do not respond to recommended treatment with bulevirtide ± pegylated interferon. The use of REP 2139-Mg is a novel treatment option that has recently demonstrated efficacy and safety in phase 2 trials and a compassionate access program that included three patients treated at the Vienna General Hospital with compensated advanced chronic liver disease and clinically significant portal hypertension (CSPH). Long-term outcome of CSPH patients treated with REP 2139-Mg is unknown; thus, surrogate endpoints are of interest in this population. In the 3 patients receiving REP 2139-Mg for 12 months at our center, we monitored the hepatic venous pressure gradient (HVPG) as the strongest prognostic surrogate biomarker in compensated cirrhosis at baseline, and after 3 and 12 months of treatment. The HVPG dynamics alongside additional liver function tests observed are summarized in this report and two out of three patients achieved undetectable hepatitis-D-virus(HDV)-RNA and low hepatitis B surface Antigen (HBsAg) following pronounced alanine aminotransferase (ALT) flares during REP 2139-Mg treatment. The first patient showed virologic non-response and no HVPG dynamics during treatment. The second patient developed jaundice upon treatment initiation, resulting in a transient increase in HVPG despite virologic response. The third patient achieved virologic response that was paralleled by sustained reductions in HVPG.
- Open Access
- 8 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70736
Post‐ TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) placement is used to treat complications of portal hypertension. This study aimed to evaluate the prognostic value of von Willebrand factor antigen (VWF) dynamics following TIPS placement. Methods: Patients with TIPS placement at the Medical University of Vienna (2018–2025) and University Medical Center Mainz (2022–2025) with available VWF at baseline (BL) were included. Patients from both cohorts with available VWF after 3 months (M3) were included in the combined longitudinal cohort (CLC). Meaningful VWF decrease (VWF‐Response) was defined as a relative VWF change (ΔVWF) of at least −5% at M3. Patients were stratified by presence of VWF‐Response and interleukin‐6 decrease (IL6‐Response) into three groups: both (R2), either/or (R1), and neither (R0). Results: Overall, 113 and 86 patients were included in the Vienna and Mainz cohorts, respectively. BL VWF was not associated with mortality in both cohorts. 118 patients constituted the CLC, which showed median BL VWF of 313.0% that decreased to 262.0% at M3 ( p = 0.007). Fifty‐three patients (44.9%) achieved VWF‐Response. Both, VWF change (ΔVWF; asHR: 2.75; 95% CI: 1.07–7.11; p = 0.037) and VWF‐Response (asHR: 0.24; 95% CI: 0.09–0.61; p = 0.003) were independently associated with survival. According to VWF and IL6 responses, patients were stratified as low‐risk (R2), versus intermediate‐risk (R1) versus high‐risk (R0) with a cumulative incidence of death at 2 years of follow‐up of R2: 10.6% versus R1: 23.1% versus R0: 46.7%, respectively. Conclusion: After TIPS placement, VWF‐Response identifies patients with a favourable prognosis and can be combined with IL6‐Response for risk stratification regarding mortality.
- 8 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70736
Open AccessPost‐ TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) placement is used to treat complications of portal hypertension. This study aimed to evaluate the prognostic value of von Willebrand factor antigen (VWF) dynamics following TIPS placement. Methods: Patients with TIPS placement at the Medical University of Vienna (2018–2025) and University Medical Center Mainz (2022–2025) with available VWF at baseline (BL) were included. Patients from both cohorts with available VWF after 3 months (M3) were included in the combined longitudinal cohort (CLC). Meaningful VWF decrease (VWF‐Response) was defined as a relative VWF change (ΔVWF) of at least −5% at M3. Patients were stratified by presence of VWF‐Response and interleukin‐6 decrease (IL6‐Response) into three groups: both (R2), either/or (R1), and neither (R0). Results: Overall, 113 and 86 patients were included in the Vienna and Mainz cohorts, respectively. BL VWF was not associated with mortality in both cohorts. 118 patients constituted the CLC, which showed median BL VWF of 313.0% that decreased to 262.0% at M3 ( p = 0.007). Fifty‐three patients (44.9%) achieved VWF‐Response. Both, VWF change (ΔVWF; asHR: 2.75; 95% CI: 1.07–7.11; p = 0.037) and VWF‐Response (asHR: 0.24; 95% CI: 0.09–0.61; p = 0.003) were independently associated with survival. According to VWF and IL6 responses, patients were stratified as low‐risk (R2), versus intermediate‐risk (R1) versus high‐risk (R0) with a cumulative incidence of death at 2 years of follow‐up of R2: 10.6% versus R1: 23.1% versus R0: 46.7%, respectively. Conclusion: After TIPS placement, VWF‐Response identifies patients with a favourable prognosis and can be combined with IL6‐Response for risk stratification regarding mortality.
- 25 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (2) , 261-262
Editorial: Bile Acids Under Bulevirtide—A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' Reply
- 25 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (2) , 261-262
Editorial: Bile Acids Under Bulevirtide—A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' Reply
- 22 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Sex Does Not Affect the Performance of Noninvasive Tests for Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
INTRODUCTION: Clinically significant portal hypertension (CSPH) denotes the hemodynamic threshold for hepatic decompensation in advanced chronic liver disease and is increasingly diagnosed by noninvasive tests (NITs). Although liver stiffness measurement by vibration-controlled transient elastography is affected by body composition, intriguingly, no data on sex differences of its diagnostic or prognostic performance are available. We aimed to address this knowledge gap. METHODS: A total of 420 stable outpatients who underwent hepatic venous pressure gradient measurement from 2007 to 2022 at the Vienna Hepatic Hemodynamic Lab were included. The sex-specific diagnostic performance of prevailing NITs was evaluated. Moreover, the sex-specific cumulative incidences of first hepatic decompensation were analyzed using competing risk models stratified by the Baveno VII criteria and the sequential Baveno VII-VITRO algorithm. RESULTS: Two-hundred eighty-one (66.9%) patients were men, whereas 139 (33.1%) were women. Liver stiffness measurement performed better in male patients (area under the receiver operating characteristic curve [AUROC] = 0.845) than in female patients (AUROC = 0.811; P = 0.447), whereas for VITRO, the AUROC in female patients (0.854) was higher, as compared with male (0.814) subjects ( P = 0.370). The ANTICIPATE ± metabolic dysfunction-associated steatohepatitis model exhibited the highest AUROC in both sexes (male = 0.885; female = 0.872; P = 0.755). Finally, Baveno VII criteria and the sequential Baveno VII-VITRO algorithms were similarly effective in ruling-in/out CSPH in men and women. Thus, we observed a comparable diagnostic performance of NITs between the sexes, with no statistically significant differences. Interestingly, female patients classified as ruled-in by Baveno VII as well as by sequential Baveno VII-VITRO algorithm showed a trend toward higher decompensation rates, as compared with males. DISCUSSION: Individual NITs and Baveno VII-based algorithms show a similar accuracy for the diagnosis of CSPH and prognostication in men and women.
- 22 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Sex Does Not Affect the Performance of Noninvasive Tests for Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
INTRODUCTION: Clinically significant portal hypertension (CSPH) denotes the hemodynamic threshold for hepatic decompensation in advanced chronic liver disease and is increasingly diagnosed by noninvasive tests (NITs). Although liver stiffness measurement by vibration-controlled transient elastography is affected by body composition, intriguingly, no data on sex differences of its diagnostic or prognostic performance are available. We aimed to address this knowledge gap. METHODS: A total of 420 stable outpatients who underwent hepatic venous pressure gradient measurement from 2007 to 2022 at the Vienna Hepatic Hemodynamic Lab were included. The sex-specific diagnostic performance of prevailing NITs was evaluated. Moreover, the sex-specific cumulative incidences of first hepatic decompensation were analyzed using competing risk models stratified by the Baveno VII criteria and the sequential Baveno VII-VITRO algorithm. RESULTS: Two-hundred eighty-one (66.9%) patients were men, whereas 139 (33.1%) were women. Liver stiffness measurement performed better in male patients (area under the receiver operating characteristic curve [AUROC] = 0.845) than in female patients (AUROC = 0.811; P = 0.447), whereas for VITRO, the AUROC in female patients (0.854) was higher, as compared with male (0.814) subjects ( P = 0.370). The ANTICIPATE ± metabolic dysfunction-associated steatohepatitis model exhibited the highest AUROC in both sexes (male = 0.885; female = 0.872; P = 0.755). Finally, Baveno VII criteria and the sequential Baveno VII-VITRO algorithms were similarly effective in ruling-in/out CSPH in men and women. Thus, we observed a comparable diagnostic performance of NITs between the sexes, with no statistically significant differences. Interestingly, female patients classified as ruled-in by Baveno VII as well as by sequential Baveno VII-VITRO algorithm showed a trend toward higher decompensation rates, as compared with males. DISCUSSION: Individual NITs and Baveno VII-based algorithms show a similar accuracy for the diagnosis of CSPH and prognostication in men and women.
- Open Access
- 21 April 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (2) , 196-207
Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D
Background: Bulevirtide (BLV) blocks hepatitis D virus (HDV) entry by targeting the sodium taurocholate co‐transporting polypeptide (NTCP). This study assessed the relationship between bile acid (BA) levels and antiviral response to BLV. Methods: Serum BA levels were monitored in HDV‐infected patients pre‐, under, and post BLV treatment. Virologic response (VR) was defined by ≥ 2log 10 decline in HDV‐RNA and discriminated versus virologic non‐response (VNR). Delta BA levels (ΔBA) were calculated and analysed in relation to HDV‐RNA dynamics. Finally, the effect of BLV treatment cessation on BA was investigated. Results: Twenty five patients (48% male; advanced chronic liver disease [ACLD]: 92.0%, 17 patients with VR at W48) were included. Median baseline BA levels were significantly higher in patients with ACLD and portal hypertension ( n = 10; 19.2 vs. 5.1 μmol/L; p = 0.015). No difference in median on‐treatment BA levels was detected between patients achieving VR or VNR at W24 (VR: 25.4 vs. VNR: 22.7 μmol/L; p = 1.000) and W48 (VR: 25.4 vs. VNR: 20.8 μmol/L; p = 1.000). Additionally, ΔBA from baseline to W48 did not differ between VR and VNR ( p = 0.534). No significant association between ΔBA and HDV‐RNA dynamics at W48 was detected. After BLV discontinuation, median BA levels significantly dropped to normal ranges (18.9 μmol/L at last on‐BLV assessment to 7.6 μmol/L after discontinuation; p = 0.028). On‐treatment BA levels did neither associate with self‐reported compliance nor with treatment‐related adverse events. Conclusion: Bulevirtide increases bile acid levels in most patients, but ΔBA does not predict virologic response or adverse events, nor does it reflect compliance to therapy. Bile acid level monitoring during and following bulevirtide treatment is thus, not advised for clinical practise.
- 21 April 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (2) , 196-207
Open AccessCorrelation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D
Background: Bulevirtide (BLV) blocks hepatitis D virus (HDV) entry by targeting the sodium taurocholate co‐transporting polypeptide (NTCP). This study assessed the relationship between bile acid (BA) levels and antiviral response to BLV. Methods: Serum BA levels were monitored in HDV‐infected patients pre‐, under, and post BLV treatment. Virologic response (VR) was defined by ≥ 2log 10 decline in HDV‐RNA and discriminated versus virologic non‐response (VNR). Delta BA levels (ΔBA) were calculated and analysed in relation to HDV‐RNA dynamics. Finally, the effect of BLV treatment cessation on BA was investigated. Results: Twenty five patients (48% male; advanced chronic liver disease [ACLD]: 92.0%, 17 patients with VR at W48) were included. Median baseline BA levels were significantly higher in patients with ACLD and portal hypertension ( n = 10; 19.2 vs. 5.1 μmol/L; p = 0.015). No difference in median on‐treatment BA levels was detected between patients achieving VR or VNR at W24 (VR: 25.4 vs. VNR: 22.7 μmol/L; p = 1.000) and W48 (VR: 25.4 vs. VNR: 20.8 μmol/L; p = 1.000). Additionally, ΔBA from baseline to W48 did not differ between VR and VNR ( p = 0.534). No significant association between ΔBA and HDV‐RNA dynamics at W48 was detected. After BLV discontinuation, median BA levels significantly dropped to normal ranges (18.9 μmol/L at last on‐BLV assessment to 7.6 μmol/L after discontinuation; p = 0.028). On‐treatment BA levels did neither associate with self‐reported compliance nor with treatment‐related adverse events. Conclusion: Bulevirtide increases bile acid levels in most patients, but ΔBA does not predict virologic response or adverse events, nor does it reflect compliance to therapy. Bile acid level monitoring during and following bulevirtide treatment is thus, not advised for clinical practise.
- Open Access
- 9 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70614
Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI ‐ 2D ‐ SWE ‐Based Liver Stiffness Measurement
Background: The World Federation for Ultrasound in Medicine and Biology (WFUMB) guidance update 2024 proposed a ‘rule‐of‐4’ using ARFI liver stiffness measurement (LSM) to stratify the risk of decompensation events. This rule identifies advanced chronic liver disease (ACLD) at a threshold of ≥ 13 kPa and indicates a high probability of clinically significant portal hypertension (CSPH) above 21 kPa. Methods: We prospectively enrolled 187 patients undergoing same‐day SSI‐2D‐LSM (Aixplorer SuperSonic Imagine) and hepatic venous pressure gradient (HVPG) measurement. Patients were stratified into three LSM groups < 13 kPa, 13–21 kPa and > 21 kPa and followed for decompensation events for 1 year (Y1). Results: The cohort comprised 31 (16.6%) patients with LSM < 13 kPa (non‐ACLD); 33 (17.6%) LSM 13–21 kPa (ACLD) and 123 (65.8%) LSM > 21 kPa (high CSPH probability). The corresponding median HVPG values were 5 [IQR: 3–7] vs. 10 [7–14] vs. 17 [13–21] mmHg, respectively, and the corresponding CSPH prevalence was 6.5%, 54.5% and 91.9%. In ROC analysis to predict CSPH, SSI‐2D‐LSM demonstrated high accuracy (AUC: 0.83). Validating the new WFUMB extension of the ‘rule‐of‐4’, the recommended > 21 kPa threshold identified CSPH with a specificity of 80.0% and a PPV of 83.1%. In competing risk analysis, the Y1‐decompensation rate was 0%, 10% and 24.7% of patients in the < 13 kPa, 13–21 kPa and > 21 kPa groups, respectively. For prediction of Y1‐decompensation risk in the compensated ACLD (cACLD) subgroup, HVPG demonstrated the highest predictive accuracy (AUC: 0.92), while SSI‐2D‐LSM (AUC: 0.75) performed similarly to vibration‐controlled transient elastography (VCTE: AUC: 0.77; AUC‐comparison: p = 0.837). Conclusions: The WFUMB ‘rule‐of‐4’ for ARFI‐LSM allows for accurate and point‐of‐care non‐invasive risk stratification of patients with liver disease. Specifically, the short‐term risk of decompensation starts at SSI‐2D‐LSM ≥ 13 kPa and becomes considerable at SSI‐2D‐LSM > 21 kPa (indicating high CSPH probability). These findings support the broader implementation of ARFI‐LSM for risk assessment in clinical routine.
- 9 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70614
Open AccessPrognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI ‐ 2D ‐ SWE ‐Based Liver Stiffness Measurement
Background: The World Federation for Ultrasound in Medicine and Biology (WFUMB) guidance update 2024 proposed a ‘rule‐of‐4’ using ARFI liver stiffness measurement (LSM) to stratify the risk of decompensation events. This rule identifies advanced chronic liver disease (ACLD) at a threshold of ≥ 13 kPa and indicates a high probability of clinically significant portal hypertension (CSPH) above 21 kPa. Methods: We prospectively enrolled 187 patients undergoing same‐day SSI‐2D‐LSM (Aixplorer SuperSonic Imagine) and hepatic venous pressure gradient (HVPG) measurement. Patients were stratified into three LSM groups < 13 kPa, 13–21 kPa and > 21 kPa and followed for decompensation events for 1 year (Y1). Results: The cohort comprised 31 (16.6%) patients with LSM < 13 kPa (non‐ACLD); 33 (17.6%) LSM 13–21 kPa (ACLD) and 123 (65.8%) LSM > 21 kPa (high CSPH probability). The corresponding median HVPG values were 5 [IQR: 3–7] vs. 10 [7–14] vs. 17 [13–21] mmHg, respectively, and the corresponding CSPH prevalence was 6.5%, 54.5% and 91.9%. In ROC analysis to predict CSPH, SSI‐2D‐LSM demonstrated high accuracy (AUC: 0.83). Validating the new WFUMB extension of the ‘rule‐of‐4’, the recommended > 21 kPa threshold identified CSPH with a specificity of 80.0% and a PPV of 83.1%. In competing risk analysis, the Y1‐decompensation rate was 0%, 10% and 24.7% of patients in the < 13 kPa, 13–21 kPa and > 21 kPa groups, respectively. For prediction of Y1‐decompensation risk in the compensated ACLD (cACLD) subgroup, HVPG demonstrated the highest predictive accuracy (AUC: 0.92), while SSI‐2D‐LSM (AUC: 0.75) performed similarly to vibration‐controlled transient elastography (VCTE: AUC: 0.77; AUC‐comparison: p = 0.837). Conclusions: The WFUMB ‘rule‐of‐4’ for ARFI‐LSM allows for accurate and point‐of‐care non‐invasive risk stratification of patients with liver disease. Specifically, the short‐term risk of decompensation starts at SSI‐2D‐LSM ≥ 13 kPa and becomes considerable at SSI‐2D‐LSM > 21 kPa (indicating high CSPH probability). These findings support the broader implementation of ARFI‐LSM for risk assessment in clinical routine.
- Open Access
- 23 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (10) , 1380-1389
The Alpha‐1 Pi * MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD
Background and Aims: Homozygosity for the SERPINA1 Pi * Z deficiency allele is the culprit of alpha‐1 antitrypsin deficiency‐related liver disease, while harbouring a single Z ‐allele (e.g., the common Pi * MZ genotype) is the strongest genetic risk factor for advanced chronic liver disease (ACLD) and its progression. However, the impact of the Pi * MZ genotype on hepatocellular carcinoma (HCC) development in patients who have already progressed to ACLD has yet to be established. Thus, we investigated the impact of the Pi * MZ genotype on the development of HCC among longitudinally followed ACLD patients. Methods: Patients undergoing hepatic venous pressure gradient (HVPG) measurement and genotyping at the Vienna Hepatic Haemodynamic Lab were included, excluding those with HCC. Competing risk analyses with HCC as the outcome of interest and death/liver transplantation as competing events were performed. Results: We included 815 patients (mean age: 54 ± 11 years; viral hepatitis: 53%, alcohol‐related liver disease: 37% and metabolic dysfunction‐associated steatotic liver disease: 10%). Overall, 30 patients (4%) harboured the Pi * MZ genotype. During a median follow‐up of 47.3 months, 68 patients developed an HCC (8/30 with Pi * MZ ). The Pi * MZ genotype was associated with increased risks of HCC development in univariable as well as in multivariable analyses, accounting for other important factors (i.e., age, sex, removal of the primary aetiological factor, aspartate‐aminotransferase, albumin and HVPG) identified in our study (adjusted subdistribution hazard ratio [aSHR]: 3.31 [95% confidence interval (CI): 1.26–8.65]; p = 0.015). The impact of the Pi * MZ genotype was confirmed adjusting for the aMAP score (aSHR: 2.94 [95% CI: 1.45–5.97]; p = 0.003). Conclusion: The SERPINA1 Pi * MZ genotype is associated with an increased risk of HCC development in patients with ACLD, independently of other HCC risk factors.
- 23 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (10) , 1380-1389
Open AccessThe Alpha‐1 Pi * MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD
Background and Aims: Homozygosity for the SERPINA1 Pi * Z deficiency allele is the culprit of alpha‐1 antitrypsin deficiency‐related liver disease, while harbouring a single Z ‐allele (e.g., the common Pi * MZ genotype) is the strongest genetic risk factor for advanced chronic liver disease (ACLD) and its progression. However, the impact of the Pi * MZ genotype on hepatocellular carcinoma (HCC) development in patients who have already progressed to ACLD has yet to be established. Thus, we investigated the impact of the Pi * MZ genotype on the development of HCC among longitudinally followed ACLD patients. Methods: Patients undergoing hepatic venous pressure gradient (HVPG) measurement and genotyping at the Vienna Hepatic Haemodynamic Lab were included, excluding those with HCC. Competing risk analyses with HCC as the outcome of interest and death/liver transplantation as competing events were performed. Results: We included 815 patients (mean age: 54 ± 11 years; viral hepatitis: 53%, alcohol‐related liver disease: 37% and metabolic dysfunction‐associated steatotic liver disease: 10%). Overall, 30 patients (4%) harboured the Pi * MZ genotype. During a median follow‐up of 47.3 months, 68 patients developed an HCC (8/30 with Pi * MZ ). The Pi * MZ genotype was associated with increased risks of HCC development in univariable as well as in multivariable analyses, accounting for other important factors (i.e., age, sex, removal of the primary aetiological factor, aspartate‐aminotransferase, albumin and HVPG) identified in our study (adjusted subdistribution hazard ratio [aSHR]: 3.31 [95% confidence interval (CI): 1.26–8.65]; p = 0.015). The impact of the Pi * MZ genotype was confirmed adjusting for the aMAP score (aSHR: 2.94 [95% CI: 1.45–5.97]; p = 0.003). Conclusion: The SERPINA1 Pi * MZ genotype is associated with an increased risk of HCC development in patients with ACLD, independently of other HCC risk factors.